Navigation Links
New drug treatment extends lives of men with prostate cancer
Date:5/26/2011

AURORA, Colo. (May 25, 2011) - A drug recently approved by the Food & Drug Administration for the treatment of prostate cancer is proving to give some patients the gift of time. A new study shows abiraterone acetate extends the lives of men with the most advanced form of the disease by about four months. The study in the May 26, 2011 issue of the New England Journal of Medicine was co-authored by Thomas W. Flaig, MD, medical oncologist at the University of Colorado Hospital's Tony Grampsas Urologic Oncology Clinic and assistant professor at the University of Colorado School of Medicine.

"Abiraterone acetate is a new, life-extending pill for the treatment of advanced prostate cancer. Unlike the traditional chemotherapy drugs used in these situations, abiraterone is generally very well tolerated," said Flaig.

The multi-center Phase III clinical trial of 1195 participants looked at the effectiveness of treating patients who had received prior chemotherapy with a combination of abiraterone acetate (ZytigaTM ) and prednisone. When this trial was initiated, there were no treatments that clearly prolonged survival in this late phase of prostate cancer. The patients were randomized to receive abiraterone acetate plus prednisone or a placebo plus prednisone each day. Treatment continued until the cancer progressed, there were unfavorable reactions, a new treatment was initiated or the patient withdrew from the trial.

The study shows participants taking abiraterone acetate lived about four months longer than participants taking the placebo. In addition, more patients receiving abiraterone acetate experienced a significant drop in the PSA blood level than those on the placebo.

"The survival benefit observed in this study is especially notable, since this was seen in the most advanced cases of prostate cancer," said Flaig. "Other studies are being done to examine the benefit of using abiraterone acetate earlier in the disease process, where it may be even more effective."

The FDA approved abiraterone acetate at the end of April. The tablet has few side effects but careful medical attention is required to monitor for specific potential side effects including liver blood test changes, low potassium levels, leg swelling and high blood pressure.


'/>"/>

Contact: Erika Matich
erika.matich@ucdenver.edu
720-848-7852
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Unique nerve-stimulation treatment proves effective against drug-resistant epilepsy
2. Clinical trials for new Alzheimers disease treatment to be awarded European Commission €6m funding
3. US study shows that tofacitinib is an efficacious treatment for active RA
4. Research suggests that lipofilling may be safe during conservation treatment for breast cancer
5. New study aims to improve long-term treatment for patients with bipolar disorder
6. PET scans predict effectiveness of treatment for multidrug-resistant tuberculosis in HIV patients
7. IUPUI study first to look at early treatment of depression to reduce heart disease risk
8. Mount Sinai researchers discover possible new target for sarcoma treatment and prevention
9. Quicker detection and treatment of severe sepsis
10. Substantial recovery rate with placebo effect in headache treatment
11. Study identifies novel role for a protein that could lead to new treatments for rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... In addition ... try taking a more holistic approach and use natural alternatives for all house ... collection is certified USDA guaranteeing that, the new line of essential oils, are ...
(Date:9/21/2017)... Va. (PRWEB) , ... September 21, 2017 , ... ... with a different approach to addiction recovery at a time when Virginia faces ... deaths resulting from drug overdose, a staggering increase of 38 percent from 2015, ...
(Date:9/20/2017)... ... September 20, 2017 , ... Reflections Recovery Center, a men-only ... The Joint Commission for chemical dependency and behavioral health services. , The Joint ... organizations that meet the commission’s rigorous standards. Accreditation by The Joint Commission is ...
(Date:9/20/2017)... Linda, CA (PRWEB) , ... September 20, 2017 , ... ... Loma Linda to their qualified network of medical professionals working on a personal injury ... Bone and Spine Surgery Inc brings these esteemed doctors’ vast experience with orthopedic injuries ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... innovation, the company recently unveiled a redesigned website. The new site – still ... of building owners, architects, contractors and other industry users that Garland serves. , ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)...   PDI , a leader in infection prevention ... educational session focused on the role of chlorhexidine gluconate ... the 2017 Annual Scientific Meeting of the Association for ... the Phoenix Convention Center in ... will also feature PDI,s Prevantics® Device Swab ...
(Date:9/5/2017)... 5, 2017 Sapheneia and Scannerside received FDA ... DoseCheck is a third-party Vendor neutral CT product that ... allows compliance with current MITA standards. ... DoseCheck solution is specifically designed to provide CT operators, ... radiation doses over a predefined threshold. Scannerside Dose Check ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
Breaking Medicine Technology: